Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Open-label Phase IIa Trial of IFX-1 in Pyoderma Gangrenosum
2020-003273-21Phase 2Completed
- Sponsor
- InflaRx
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vilobelimab in pyoderma gangrenosum (PG), sponsored by InflaRx. Primary endpoint: Safety (Treatment-emergent adverse events). Started Sep 2020; status: completed.
02
Drugs
vilobelimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on 2020-003273-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003273-21.